NICE unsure of benefits with certain stages of breast cancer

The National Institute for Health and Clinical Excellence (NICE) does not recommend lapatinib (Tyverb, GlaxoSmithKline) or trastuzumab (Herceptin, Roche) with aromatase inhibitors for a particular type and stage of breast cancer. This is because it is unclear how much either drug can improve overall survival compared to existing treatments and they do not appear to represent value for money for the for the NHS.

Cancer Watch May 2012 (Not one death from vitamins, but plenty from medicines!)
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Our

Join Our Newsletter Signup today for free and be the first to get notified on new updates.